Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV/HBV
Biotech
Gilead, Hookipa amend HIV treatment pact for $237M in biobucks
Gilead gives Hookipa $15M upfront and $5M in equity financing to bankroll a phase 1b study of the Austrian biotech's HIV immunotherapy.
Kyle LaHucik
Feb 16, 2022 9:48am
Brii, now public, expects Q4 COVID-19 antibody cocktail readout
Jul 14, 2021 10:45am
Gilead axes $445M Precision Biosciences gene therapy hep B pact
Jul 8, 2020 8:40am
